Adjuvant pembrolizumab approved in Scotland
Yesterday is was announced that the Scottish Medicines Consortium (SMC) [...]
Adjuvant pembrolizumab approved by NICE
Late last week we learnt that the National Institute for [...]
ESMO 2022: Atezolizumab as an adjuvant therapy
The results from the IMmotion010 study were presented at the [...]
ESMO 2022: Nivolumab before and after surgery to prevent recurrence of kidney cancer
In this phase 3 randomised study, presented at the European [...]
Nivolumab plus ipilimumab for localised kidney cancer
In a recent phase 3 clinical trial the combination of [...]
Adjuvant nivolumab plus ipilimumab for kidney cancer
Adjuvant therapy is medication that is given after surgery to [...]
AUA 2022: Should everyone have adjuvant therapy after surgery for high-risk kidney cancer?
The 2022 American Urological Association (AUA) Annual Meeting included a [...]
Can adjuvant everolimus prevent recurrence following surgery?
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
Is early treatment with adjuvant therapy healthy, cost effective and wise: the patient perspective?
Adjuvant therapy is medication that is given in addition to [...]
Treatment of people who relapse on adjuvant pembrolizumab
Adjuvant treatment is treatment that is given after surgery to [...]
